title: Neuroprotection for Parkinson's disease.
abstract: Levodopa is the most effective drug available for the treatment of Parkinson's disease (PD). As a precursor of dopamine, levodopa causes an increase in brain dopamine, which is depleted in PD. However, long-term levodopa therapy is associated with complications such as dyskinesias, motor fluctuations, and mental status changes. The treatment of these side effects is a major challenge for the clinician.
authors.affiliation: Department of Neurology, University of Kansas Medical Center, Kansas City 66160-7314, USA.
authors.forename: W C
authors.initials: WC
authors.lastname: Koller
mesh_terms: D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015259:Dopamine Agents / Q000009:adverse effects*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D012642:Selegiline / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use
chemical_list: D000978:Antiparkinson Agents; D015259:Dopamine Agents; D018696:Neuroprotective Agents; D014810:Vitamin E; D012642:Selegiline; D007980:Levodopa